The Interplay of Programmed Cell Death Networks in Cardiovascular Diseases: Mechanisms and Therapeutic Opportunities

Yuruo He1,2, Xiayu Zhang1,2, Jinhui Duan1,2

  • 1School of Medicine, Northwest University, 710069 Xi'an, Shaanxi, China.

Insights

Programmed cell death (PCD) pathways are key in cardiovascular diseases (CVDs). This review details cell-specific PCD, regulatory networks, and natural compounds, proposing precision therapies for CVDs.

Area of Science:

  • Cardiovascular Translational Medicine
  • Molecular Biology
  • Cell Death Pathways

Background:

  • Programmed cell death (PCD) pathways, including apoptosis, pyroptosis, ferroptosis, and necroptosis, are integral to cardiovascular diseases (CVDs) like atherosclerosis and myocardial ischemia-reperfusion injury.
  • Understanding cell-type-specific PCD is crucial, as endothelial cells primarily exhibit pyroptosis and ferroptosis, while macrophages display diverse PCD modalities and complex interactions.

Purpose of the Study:

  • To review cell-type-specific PCD signatures in CVDs.
  • To summarize key regulatory pathways and natural compounds modulating PCD networks.
  • To identify clinical translation bottlenecks and propose innovative therapeutic strategies.

Main Methods:

  • Systematic review of literature on PCD pathways in cardiovascular diseases.
  • Analysis of cell-type-specific PCD mechanisms and regulatory networks.
  • Evaluation of natural compounds and delivery systems for therapeutic potential.

Main Results:

  • Endothelial cells predominantly undergo pyroptosis and ferroptosis; macrophages exhibit multiple PCD modalities.
  • Key regulatory pathways (e.g., Piezo1/NLRP3, Nrf2/HO-1/GPX4) and natural compounds (melatonin, Guizhitongluo Tablet) are identified.
  • Clinical translation challenges include nonspecific distribution and lack of biomarkers; solutions like targeted delivery and PTGS2 biomarker are proposed.

Conclusions:

  • PCD network dysregulation significantly contributes to CVD pathogenesis.
  • Targeted modulation of PCD pathways using natural compounds and advanced delivery systems offers therapeutic promise.
  • Developing pathway-specific biomarkers and targeted delivery systems is essential for advancing cardiovascular translational medicine.

Related Concept Videos

Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...